Collaborative research to better understand the early stages of Alzheimer’s disease and prevent dementia before symptoms occur. The EPAD project is part of a global effort in the fight against Alzheimer’s disease and is a major European initiative to create a novel environment for testing numerous interventions targeted at the prevention of Alzheimer’s dementia.
Verge moves drug discovery from the lab to the computer.
Neurological diseases are caused by complex interactions between many genes. Many drug discoveries fail because researchers target only one gene at a time. Using the same breakthroughs that power Google’s search engines, we’ve discovered a way to map out the hundreds of genes that cause a disease, and then find drugs that target all the genes at once.
Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders. The pipeline includes its lead drug candidate, CM-AT, for Autism, along with a number of therapies for other neurological conditions.
A Multi-Platform Approach to Gene-Based Therapeutics. Sangamo has developed a range of capabilities that enable them to address serious and life-threatening genetic diseases with the appropriate therapeutic approach. These include best-in-class capabilities in gene therapy and genome editing, which are being deployed to produce therapeutic proteins from the liver and to generate new types of cell-based therapies. Sangamo can also regulate genes for therapeutic benefit.
Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society. Leveraging its three integrated platforms, Yumanity Therapeutics’ innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
Dementia affects an estimated 47 million people worldwide, a figure set to almost double every 20 years. The world’s first G8 dementia summit was held in 2013, bringing together ministers, researchers, pharmaceutical companies and charities to discuss what can be done. Since then, there have been a number of important initiatives launched including the Dementia Discovery Fund.